A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs

28 de outubro de 2020

Um estudo clínico piloto do anticorpo terapêutico contra PD-1 canino para cânceres espontâneos avançados em cães




Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers.


monoclonal antibodies, cancer therapy, melanoma


anticorpo monoclonal, cancer, melanoma

Comentar este artigo

Você precisa estar logado para comentar os artigos.
Desenvolvido por logo-crowd